Table 2 Clinical courses of patients receiving genetic alteration-driven therapies. PFS for molecular-directed therapy is calculated as months until data cut-off (31.12.2022)
Cancer type, tumor stage at time of molecular-directed therapy | Genetic alteration | Drug | Lines of pretreatments (n) | Time on prior therapy (months) | PFS for molecular-directed therapy (months) | Best response |
|---|---|---|---|---|---|---|
CCC, UICC IV | IDH1 R132C | Ivosidenib | 1 | 12.4 | 2.5 | progress |
CCC, UICC IV | IDH1 R132C | Ivosidenib | 3 | 11.4 | 2.3 | stable disease |
CCC, UICC IV | ERBB3 G284R | Lapatinib + Trastuzumab | 2 | 10.3 | 7.3 (ongoing) | mixed response |
CCC, UICC IV | dMMR | Pembrolizumab | 1 | 3.7 | 65.1 (ongoing) | complete response |
CRC, UICC IV | dMMR/ BRAF V600E | Pembrolizumab/ Encorafenib + Cetuximab | 0 | 0 | 12.2 (9.2/3.0) | stable disease/ progress |
CRC, UICC IV | dMMR/ BRAF V600E | Pembrolizumab | 0 | 0 | 15.5 (ongoing) | stable disease |
CRC, UICC IV | dMMR | Pembrolizumab/ Nivolumab + Ipilimumab | 0 | 0 | 28.8 (27.6/1.2) | partial response/ n.a. |
CRC, UICC IV | BRAF V600E | Encorafenib + Binimetinib + Cetuximab | 1 | 1.4 | 5.1 | partial response |
CRC, UICC IV | dMMR | Pembrolizumab | 0 | 0 | 8.9 | mixed response |
CRC, UICC IV | BRAF V600E | Encorafenib + Cetuximab | 0 | 0 | 3.8 | mixed response |
CRC, UICC IV | BRAF V600E | Encorafenib + Cetuximab | 0 | 0 | 0.8 (ongoing) | Not assessed (ongoing) |
Duodenal adenocarcinoma, UICC IV | dMMR | Pembrolizumab/ Nivolumab | 1 | 3 | 39.6 (36.3/3.3) | stable disease |
PDAC, UICC IV | BRCA1 E1161Ffs*3/ BRCA2 S497L | Olaparib | 3 | 19.3 | 9.0 (ongoing) | Partial response |